EP2184984A4 - DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION - Google Patents

DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION

Info

Publication number
EP2184984A4
EP2184984A4 EP08796733.7A EP08796733A EP2184984A4 EP 2184984 A4 EP2184984 A4 EP 2184984A4 EP 08796733 A EP08796733 A EP 08796733A EP 2184984 A4 EP2184984 A4 EP 2184984A4
Authority
EP
European Patent Office
Prior art keywords
methods
polymorphs
arylamino
compositions
mek inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08796733.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2184984A1 (en
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Stuart Dimock
Barry Quart
Jeffrey N Miner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2184984(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of EP2184984A1 publication Critical patent/EP2184984A1/en
Publication of EP2184984A4 publication Critical patent/EP2184984A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Hospice & Palliative Care (AREA)
  • Dentistry (AREA)
EP08796733.7A 2007-07-30 2008-07-28 DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION Ceased EP2184984A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number Publication Date
EP2184984A1 EP2184984A1 (en) 2010-05-19
EP2184984A4 true EP2184984A4 (en) 2013-07-24

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08796733.7A Ceased EP2184984A4 (en) 2007-07-30 2008-07-28 DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION

Country Status (22)

Country Link
EP (1) EP2184984A4 (OSRAM)
JP (3) JP2010535232A (OSRAM)
KR (3) KR20150091434A (OSRAM)
CN (2) CN101808516B (OSRAM)
AP (1) AP2817A (OSRAM)
AU (2) AU2008282338B2 (OSRAM)
BR (1) BRPI0815659A2 (OSRAM)
CA (1) CA2693390C (OSRAM)
CO (1) CO6470808A2 (OSRAM)
CR (1) CR11244A (OSRAM)
DO (1) DOP2010000045A (OSRAM)
EA (2) EA020624B1 (OSRAM)
EC (1) ECSP109910A (OSRAM)
HN (1) HN2010000203A (OSRAM)
IL (1) IL203296A (OSRAM)
MA (1) MA31881B1 (OSRAM)
MX (1) MX2010001244A (OSRAM)
NZ (1) NZ582929A (OSRAM)
PH (1) PH12015501914A1 (OSRAM)
SV (1) SV2010003469A (OSRAM)
TN (1) TN2010000049A1 (OSRAM)
WO (1) WO2009018233A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SG189784A1 (en) * 2008-04-14 2013-05-31 Ardea Biosciences Inc Compositions and methods for preparing and using same
CA3003213C (en) * 2008-09-09 2021-07-20 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
EA201101302A1 (ru) * 2009-03-11 2012-05-30 Арди Байосайенсиз, Инк. Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
CA2777304A1 (en) * 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
EA201391587A1 (ru) * 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Комбинированная терапия на основе hsp90
AP2013007257A0 (en) * 2011-05-27 2013-11-30 Bayer Ip Gmbh Chiral synthesis of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CA2874905A1 (en) * 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
EP4306171A3 (en) * 2012-10-19 2024-04-03 Array Biopharma, Inc. Formulation comprising a mek inhibitor
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR102425265B1 (ko) 2014-08-25 2022-07-26 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
BR112019026483A2 (pt) * 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
AU680635C (en) * 1992-08-25 2007-05-17 G.D. Searle Llc Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DE69926914T2 (de) * 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CN100441176C (zh) * 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
CN1681489A (zh) * 2002-07-17 2005-10-12 蒂坦药物股份有限公司 增加抗肿瘤活性的化疗药物的联用
AR040717A1 (es) * 2002-07-30 2005-04-20 Zentaris Ag Uso de alquilfosfocolinas en cominacion con medicamentos antitumorales para el tratamiento de oncosis maligna y benigna en seres humanos y animales
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
EP1876167A4 (en) * 2005-04-22 2010-07-07 Kissei Pharmaceutical CRYSTAL POLYMORPHYIS OF 4- {2 - [(1S, 2R) -2-HYDROXY-2- (4-HYDROXYPHENYL) -1-METHYLETHYLAMINO] ETHOXY} -3-ISOPROPYL-3,5-DIMETHYLBIPHENYLCARBOXYLIC ACID HYDROCHLORIDE
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
See also references of WO2009018233A1 *

Also Published As

Publication number Publication date
CN101808516A (zh) 2010-08-18
HN2010000203A (es) 2012-11-19
JP2010535232A (ja) 2010-11-18
KR20150091434A (ko) 2015-08-10
AP2010005134A0 (en) 2010-02-28
CN103479604B (zh) 2016-08-10
PH12015501914A1 (en) 2017-07-31
NZ582929A (en) 2012-03-30
CA2693390C (en) 2017-01-17
WO2009018233A1 (en) 2009-02-05
EA032294B1 (ru) 2019-05-31
JP2017125021A (ja) 2017-07-20
DOP2010000045A (es) 2010-10-31
EA201000268A1 (ru) 2010-08-30
CR11244A (es) 2010-05-20
MX2010001244A (es) 2010-08-31
SV2010003469A (es) 2010-04-30
CN103479604A (zh) 2014-01-01
CA2693390A1 (en) 2009-02-05
HK1147396A1 (en) 2011-08-12
EA020624B1 (ru) 2014-12-30
EP2184984A1 (en) 2010-05-19
MA31881B1 (fr) 2010-12-01
JP6309880B2 (ja) 2018-04-11
ECSP109910A (es) 2010-04-30
TN2010000049A1 (en) 2011-09-26
EA201400552A1 (ru) 2014-09-30
CO6470808A2 (es) 2012-06-29
KR20100092424A (ko) 2010-08-20
AU2015200390B2 (en) 2017-02-23
CN101808516B (zh) 2013-08-28
AU2008282338A1 (en) 2009-02-05
JP2015078199A (ja) 2015-04-23
AP2817A (en) 2013-12-31
AU2008282338B2 (en) 2015-02-12
KR20140098185A (ko) 2014-08-07
BRPI0815659A2 (pt) 2014-09-30
IL203296A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
EP2184984A4 (en) DERIVATIVES OF N- (ARYLAMINO) SULPHONAMIDES WITH POLYMORPHES AS MEK-INHIBITORS AND COMPOSITIONS THEREOF, METHOD FOR THEIR USE AND METHOD FOR THEIR PREPARATION
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EP2187742A4 (en) BENZYLBENZOLE DERIVATIVES AND METHOD FOR THEIR USE
EP2279008A4 (en) PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGUE OR PACLITAXEL CONJUGATES AND RELEVANT MANUFACTURING AND USE METHOD
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
EP2528441A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP2068913A4 (en) IMMUNOMODULATORS, PREPARATIONS AND COMPOSITIONS WITH IMMUNOMODULATORS, TESTS FOR EVALUATING THE ACTIVITY OF IMMUNOMODULATORS AND PREPARATIONS AND COMPOSITIONS CONTAINING SUCH, AND METHOD AND METHOD
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
NO20090628L (no) Pyridizinon derivativater
MA31683B1 (fr) Composes et procedes pour moduler fxr
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EP2234963A4 (en) LEVODOPA FORMULATIONS WITH CONTROLLED RELEASE AND ITS USE
EP2344198A4 (en) PHARMACEUTICAL PREPARATIONS OF LIPID BASE FOR ORAL AND TOPICAL ADMINISTRATION, COMPOSITIONS AND METHOD FOR THEIR USE
EP2400968A4 (en) COMPOSITIONS, THEIR SYNTHESIS AND METHOD FOR THE USE OF ARYLPIPERAZINE DERIVATIVES
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX384206B (es) Formulaciones de inhibidores de dpp iv
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20100503

Extension state: BA

Payment date: 20100503

Extension state: AL

Payment date: 20100503

Extension state: RS

Payment date: 20100503

A4 Supplementary search report drawn up and despatched

Effective date: 20130621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/18 20060101ALI20130617BHEP

Ipc: A01N 41/06 20060101AFI20130617BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARDEA BIOSCIENCES, INC.

17Q First examination report despatched

Effective date: 20150626

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

18R Application refused

Effective date: 20180425